Navigation Links
Lilly Announces Completion of Alnara Acquisition
Date:7/20/2010

INDIANAPOLIS, July 20 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.

Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT). Liprotamase is under review by the U.S. Food and Drug Administration for the treatment of exocrine pancreatic insufficiency (EPI). Causes of EPI include cystic fibrosis, chronic pancreatitis, pancreatectomy and other conditions.

Under the terms of the agreement, Lilly acquired all outstanding shares of Alnara for an upfront payment of $180 million, subject to adjustment based on existing cash on hand at closing. Alnara stockholders will also be eligible for up to $200 million in additional payments contingent upon potential future regulatory and commercial milestones. The impact of the acquisition will be reflected in Lilly's third quarter 2010 financial statements.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This press release contains forward-looking statements about the benefits of a merger between Lilly and Alnara and the potential of Alnara's product pipeline. It reflects Lilly's and Alnara's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of implementing the transaction and in drug development.  There is no guarantee Lilly will realize the expected benefits of the transaction, or that liprotamase will be approved by the FDA on the anticipated timeline or at all, that liprotamase will be commercially successful, or that Alnara's pipeline will yield commercially successful pharmaceutical products.  For further discussion of these and other risks and uncertainties, please see Lilly's latest Form 10-Q filed April 2010 and Form 10-K filed February 2010. The company undertakes no duty to update forward-looking statements.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... WASHINGTON, N.Y. , Feb. 17, 2017 /PRNewswire/ ... firm dedicated to protecting the rights of victims ... problems have prompted regulators to call for better ... in 1990. Safety concerns involving power ... Drug Administration (FDA) to investigate how hospitals report ...
(Date:2/17/2017)... LONDON , February 17, 2017 Cryoablation, ... Urology The global ablation technologies market is expected to ... 9.7% from 2022-2027. The market is expected to grow at a ... at $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 17, 2017 , ... While EHR data has revolutionized the ... innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on field ... a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue Cycle Solutions (MAP ... has been promoted to Chief Executive Officer. , The need for maximizing ... shift that demands the transition from pay-for-service to pay-for-performance models. By delivering efficient ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... Top neuroendocrine ... International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. ... (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 faculty ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children ... development. ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An ... , ACE.P will address what has been identified as a critical gap in preparing ...
Breaking Medicine News(10 mins):